Pre-made Lesofavumab benchmark antibody ( Whole mAb, anti-Influenza B Virus therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lesofavumab biosimilar, Whole Mab: Anti-Influenza B Virus therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lesofavumab is a human immunoglobulin G1, antibody cloned from a single human plasmablast, isolated from an influenza-vaccinated donor.
| Products Name (INN Index) | Pre-Made Lesofavumab biosimilar, Whole Mab: Anti-Influenza B Virus therapeutic antibody |
|---|---|
| INN Name | Lesofavumab |
| Target | Influenza B Virus |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Influenza B virus infections |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Influenza B Virus |
| Package |
